Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection

Neurobiol Dis. 2013 Nov:59:69-79. doi: 10.1016/j.nbd.2013.07.007. Epub 2013 Jul 24.

Abstract

Wld(S) mutation protects axons from degeneration in diverse experimental models of neurological disorders, suggesting that the mutation might act on a key step shared by different axon degeneration pathways. Here we test the hypothesis that Wld(S) protects axons by preventing energy deficiency commonly encountered in many diseases. We subjected compartmentally cultured, mouse cortical axons to energy deprivation with 6mM azide and zero glucose. In wild-type (WT) culture, the treatment, which reduced axon ATP level ([ATP]axon) by 65%, caused immediate axon depolarization followed by gradual free calcium accumulation and subsequent irreversible axon damage. The calcium accumulation resulted from calcium influx partially via L-type voltage-gated calcium channel (L-VGCC). Blocking L-VGCC with nimodipine reduced calcium accumulation and protected axons. Without altering baseline [ATP]axon, the presence of Wld(S) mutation significantly reduced the axon ATP loss and depolarization, restrained the subsequent calcium accumulation, and protected axons against energy deprivation. Wld(S) neurons possessed higher than normal nicotinamide mononucleotide adenylyltransferase (NMNAT) activity. The intrinsic Wld(S) NMNAT activity was required for the Wld(S)-mediated energy preservation and axon protection during but not prior to energy deprivation. NMNAT catalyzes the reversible reaction that produces nicotinamide adenine dinucleotide (NAD) from nicotinamide mononucleotide (NMN). Interestingly, preventing the production of NAD from NMN with FK866 increased [ATP]axon and protected axons from energy deprivation. These results indicate that the Wld(S) mutation depends on its intrinsic Wld(S) NMNAT activity and the subsequent increase in axon ATP but not NAD to protect axons, implicating a novel role of Wld(S) NMNAT in axon bioenergetics and protection.

Keywords: ATP; ATP level in axons; ATP levels in cell bodies; AUC; Axon injury; Bioenergetics; Calcium; DFI; DIV; Dibac(4)(3); Dibac(4)(3) fluorescence intensity; Energy deprivation; GA; L-VGCC; L-type voltage-gated calcium channel; MTR; MitoTracker Red CMXRos; NAD; NAM; NAMPT; NMN; NMNAT; PPi; PRPP; ROI; WT; Wld(S); [ATP](axon); [ATP](cell); [Ca(2+)](axon); area under the curve; bis(1,3-dibutylbarbituric acid) trimethine oxonol; days in vitro; free calcium concentration in axon; gallotannin; hours post injury; hpi; nicotinamide; nicotinamide adenine dinucleotide; nicotinamide mononucleotide; nicotinamide mononucleotide adenylyltransferase; nicotinamide phosphoribosyltransferase; phosphoribosylpyrophosphate; pyrophosphate; region of interest; wild-type.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine Triphosphate / genetics
  • Animals
  • Axons / pathology
  • Axons / physiology
  • Calcium / metabolism
  • Cerebral Cortex / pathology*
  • Disease Models, Animal
  • Embryo, Mammalian
  • Energy Metabolism / drug effects
  • Energy Metabolism / genetics
  • Energy Metabolism / physiology*
  • Enzyme Activation / drug effects
  • Enzyme Activation / genetics
  • Enzyme Inhibitors / toxicity
  • Glucose / deficiency
  • Membrane Potentials / drug effects
  • Membrane Potentials / genetics
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / physiology
  • Mutation / genetics*
  • Nerve Tissue Proteins / genetics*
  • Nerve Tissue Proteins / metabolism
  • Organ Culture Techniques
  • Sodium Azide / toxicity
  • Wallerian Degeneration / genetics*
  • Wallerian Degeneration / pathology*

Substances

  • Enzyme Inhibitors
  • Nerve Tissue Proteins
  • Wld protein, mouse
  • Adenosine Triphosphate
  • Sodium Azide
  • Glucose
  • Calcium